Physician

Hafeez T Chatoor, M.D.

According to 2025 Medicare claims, Hafeez Chatoor, M.D. (NPI: 1174533194) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33607-6214.

Chatoor's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 647 traditional Medicare patients, billed 155,782 HCPCS/CPT codes, and received $2,303,597 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 722 prescription claims across 129 beneficiaries totaling $2,058,053 in drug costs, led by Revlimid (Lenalidomide). DME data shows 36 claims. Open Payments data shows 184 records totaling $4,238. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,524,847 to $2,303,597. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $971,023 and ending at $2,058,053. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,101 to $1,060.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	831	172,089	$1,524,847
2016	882	144,698	$1,726,990
2017	915	252,412	$3,177,272
2018	926	257,656	$3,810,087
2019	931	263,525	$3,659,998
2020	768	228,498	$3,776,714
2021	774	227,718	$4,045,446
2022	670	210,603	$3,984,969
2023	702	170,792	$2,845,907
2024	647	155,782	$2,303,597

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	123	831	$971,023
2016	129	862	$1,369,141
2017	125	935	$1,727,512
2018	128	1,026	$1,698,421
2019	125	1,134	$2,315,858
2020	108	908	$2,253,092
2021	120	774	$1,956,251
2022	96	705	$1,571,056
2023	117	678	$1,695,804
2024	129	722	$2,058,053

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	50	$2,048
2016	N/R	12	$772
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	35	$24,299
2023	N/R	29	$37,286
2024	N/R	36	$44,388

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	329	1,045	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	225	290	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	299	751	$13
36415	Insertion of needle into vein for collection of blood sample	464	1,836	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	463	1,928	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	22	581	$393,521
Lenvima	Lenvatinib Mesylate	12	360	$291,709
Xtandi	Enzalutamide	20	600	$240,924
Venclexta	Venetoclax	12	360	$187,805
Promacta	Eltrombopag Olamine	12	360	$88,695

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	18	$38,454
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	18	$5,934

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	184	$4,238	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hafeez T. Chatoor, M.D.?

Tedicare shows public-source Medicare data for Hafeez T. Chatoor, M.D. (NPI 1174533194), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hafeez T. Chatoor, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Hafeez T. Chatoor, M.D.?

Hafeez T. Chatoor, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Hafeez T. Chatoor, M.D. have Open Payments data?

Hafeez T. Chatoor, M.D. has 184 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.